irhythm technologies inc - IRTC
IRTC
Close Chg Chg %
178.57 -1.13 -0.63%
Closed Market
177.44
-1.13 (0.63%)
Volume: 173.69K
Last Updated:
Dec 31, 2025, 4:00 PM EDT
Company Overview: irhythm technologies inc - IRTC
IRTC Key Data
| Open $178.69 | Day Range 176.76 - 180.00 |
| 52 Week Range 86.55 - 210.01 | Market Cap $5.72B |
| Shares Outstanding 32.22M | Public Float 31.69M |
| Beta 1.12 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.62 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 406.33K |
IRTC Performance
| 1 Week | 0.48% | ||
| 1 Month | -0.52% | ||
| 3 Months | 1.04% | ||
| 1 Year | 96.78% | ||
| 5 Years | -25.20% |
IRTC Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
16
Full Ratings ➔
About irhythm technologies inc - IRTC
iRhythm Technologies, Inc. is a digital healthcare company, which engages in the provision of design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.
IRTC At a Glance
iRhythm Technologies, Inc.
699 8th Street
San Francisco, California 94103
| Phone | 1-415-632-5700 | Revenue | 591.84M | |
| Industry | Medical Specialties | Net Income | -113,289,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 20.126% | |
| Fiscal Year-end | 12 / 2025 | Employees | 2,000 | |
| View SEC Filings |
IRTC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.753 |
| Price to Book Ratio | 31.137 |
| Price to Cash Flow Ratio | 829.78 |
| Enterprise Value to EBITDA | -53.147 |
| Enterprise Value to Sales | 5.093 |
| Total Debt to Enterprise Value | 0.244 |
IRTC Efficiency
| Revenue/Employee | 295,919.50 |
| Income Per Employee | -56,644.50 |
| Receivables Turnover | 7.403 |
| Total Asset Turnover | 0.867 |
IRTC Liquidity
| Current Ratio | 5.822 |
| Quick Ratio | 5.696 |
| Cash Ratio | 4.828 |
IRTC Profitability
| Gross Margin | 68.858 |
| Operating Margin | -13.938 |
| Pretax Margin | -19.046 |
| Net Margin | -19.142 |
| Return on Assets | -16.604 |
| Return on Equity | -75.274 |
| Return on Total Capital | -13.685 |
| Return on Invested Capital | -19.933 |
IRTC Capital Structure
| Total Debt to Total Equity | 810.61 |
| Total Debt to Total Capital | 89.018 |
| Total Debt to Total Assets | 79.114 |
| Long-Term Debt to Equity | 793.156 |
| Long-Term Debt to Total Capital | 87.102 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Irhythm Technologies Inc - IRTC
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 322.82M | 410.92M | 492.68M | 591.84M | |
Sales Growth
| +21.74% | +27.29% | +19.90% | +20.13% | |
Cost of Goods Sold (COGS) incl D&A
| 109.26M | 129.29M | 160.88M | 184.31M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 16.59M | 19.61M | 22.14M | 25.78M | |
Depreciation
| 16.59M | 19.61M | 22.14M | 25.78M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +55.47% | +18.33% | +24.43% | +14.57% | |
Gross Income
| 213.57M | 281.63M | 331.81M | 407.53M | |
Gross Income Growth
| +9.58% | +31.87% | +17.82% | +22.82% | |
Gross Profit Margin
| +66.16% | +68.54% | +67.35% | +68.86% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 313.51M | 368.81M | 445.89M | 490.02M | |
Research & Development
| 38.67M | 46.61M | 60.24M | 71.46M | |
Other SG&A
| 274.84M | 322.20M | 385.64M | 418.56M | |
SGA Growth
| +31.42% | +17.64% | +20.90% | +9.90% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 26.61M | 11.08M | 38.70M | |
EBIT after Unusual Expense
| (99.94M) | (113.78M) | (125.16M) | (121.19M) | |
Non Operating Income/Expense
| 118.00K | 2.04M | 6.16M | 21.29M | |
Non-Operating Interest Income
| - | - | - | 21.94M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 1.17M | 4.14M | 3.65M | 12.82M | |
Interest Expense Growth
| -23.04% | +253.98% | -11.79% | +251.26% | |
Gross Interest Expense
| 1.17M | 4.14M | 3.65M | 12.82M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (100.99M) | (115.89M) | (122.66M) | (112.72M) | |
Pretax Income Growth
| -131.63% | -14.75% | -5.84% | +8.10% | |
Pretax Margin
| -31.28% | -28.20% | -24.90% | -19.05% | |
Income Tax
| 367.00K | 269.00K | 750.00K | 565.00K | |
Income Tax - Current - Domestic
| 223.00K | 160.00K | 401.00K | 218.00K | |
Income Tax - Current - Foreign
| 150.00K | 111.00K | 349.00K | 474.00K | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | (6.00K) | (2.00K) | (127.00K) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (101.36M) | (116.16M) | (123.41M) | (113.29M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (101.36M) | (116.16M) | (123.41M) | (113.29M) | |
Net Income Growth
| -131.26% | -14.60% | -6.24% | +8.20% | |
Net Margin Growth
| -31.40% | -28.27% | -25.05% | -19.14% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (101.36M) | (116.16M) | (123.41M) | (113.29M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (101.36M) | (116.16M) | (123.41M) | (113.29M) | |
EPS (Basic)
| -3.4558 | -3.8827 | -4.0424 | -3.6315 | |
EPS (Basic) Growth
| -118.83% | -12.35% | -4.11% | +10.16% | |
Basic Shares Outstanding
| 29.33M | 29.92M | 30.53M | 31.20M | |
EPS (Diluted)
| -3.4558 | -3.8827 | -4.0424 | -3.6315 | |
EPS (Diluted) Growth
| -118.83% | -12.35% | -4.11% | +10.16% | |
Diluted Shares Outstanding
| 29.33M | 29.92M | 30.53M | 31.20M | |
EBITDA
| (83.35M) | (67.57M) | (91.94M) | (56.72M) | |
EBITDA Growth
| -171.12% | +18.93% | -36.07% | +38.31% | |
EBITDA Margin
| -25.82% | -16.44% | -18.66% | -9.58% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 219.60 | |
| Number of Ratings | 16 | Current Quarters Estimate | -0.555 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -0.528 | |
| Last Quarter’s Earnings | 0.035 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.505 | Next Fiscal Year Estimate | 0.551 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 8 | 8 | 11 | 7 |
| Mean Estimate | -0.56 | -0.15 | -0.53 | 0.55 |
| High Estimates | -0.20 | 0.09 | 0.01 | 0.74 |
| Low Estimate | -0.80 | -0.34 | -0.91 | 0.33 |
| Coefficient of Variance | -38.72 | -86.63 | -47.24 | 22.61 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 13 | 13 | 13 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 2 | 2 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Irhythm Technologies Inc - IRTC
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Irhythm Technologies Inc - IRTC
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Aug 13, 2025 | Abhijit Y. Talwalkar Director | 22,428 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $157.57 per share | 3,533,979.96 |
| Aug 13, 2025 | Abhijit Y. Talwalkar Director | 20,299 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $158.68 per share | 3,221,045.32 |
| Aug 13, 2025 | Abhijit Y. Talwalkar Director | 15,936 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 13, 2025 | Donald J. Rosenberg Chief Accounting Officer | 10,879 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $158.93 per share | 1,728,999.47 |
| Aug 13, 2025 | Abhijit Y. Talwalkar Director | 25,611 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $10.71 per share | 274,293.81 |
| Feb 28, 2025 | Mervin Smith EVP Strategic Business Ops | 17,092 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Sumi Shrishrimal EVP, Chief Risk Officer | 23,650 | Other acquisition or disposition Non-derivative transaction at $74.98 per share | 1,773,277.00 |
| Feb 28, 2025 | Sumi Shrishrimal EVP, Chief Risk Officer | 23,464 | Other acquisition or disposition Non-derivative transaction at $72.49 per share | 1,700,905.36 |
| Feb 28, 2025 | Daniel G. Wilson Chief Financial Officer | 47,648 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $112.13 per share | 5,342,770.24 |
| Feb 28, 2025 | Daniel G. Wilson Chief Financial Officer | 50,160 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Daniel G. Wilson Chief Financial Officer | 41,184 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Quentin S. Blackford President and CEO; Director | 216,886 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $112.13 per share | 24,319,427.18 |
| Feb 28, 2025 | Quentin S. Blackford President and CEO; Director | 239,138 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Quentin S. Blackford President and CEO; Director | 200,539 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Patrick Michael Murphy CBO and CLO | 58,834 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $108.93 per share | 6,408,787.62 |
| Feb 28, 2025 | Patrick Michael Murphy CBO and CLO | 71,347 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $112.13 per share | 8,000,139.11 |
| Feb 28, 2025 | Patrick Michael Murphy CBO and CLO | 75,164 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Patrick Michael Murphy CBO and CLO | 66,188 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Patrick Michael Murphy CBO and CLO | 42,630 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Donald J. Rosenberg Chief Accounting Officer | 11,821 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |